Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 21, 2020 - Issue 16
Submit an article Journal homepage
1,203
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Has crizotinib significantly impacted non-small-cell lung cancer therapy?

Emanuele Vitaa Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy;b Medical Oncology, Università Cattolica del Sacro Cuore, Roma, ItalyView further author information
,
Alessio Stefania Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy;b Medical Oncology, Università Cattolica del Sacro Cuore, Roma, ItalyView further author information
,
Ettore D’Argentoa Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy;b Medical Oncology, Università Cattolica del Sacro Cuore, Roma, ItalyView further author information
,
Giampaolo Tortoraa Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy;b Medical Oncology, Università Cattolica del Sacro Cuore, Roma, ItalyView further author information
&
Emilio Briaa Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy;b Medical Oncology, Università Cattolica del Sacro Cuore, Roma, ItalyCorrespondence[email protected]
View further author information
Pages 1927-1930 | Received 12 Apr 2020, Accepted 14 Jul 2020, Published online: 27 Jul 2020

References

  • Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131:1190–1203.
  • Caccese M, Ferrara R, Piloto S, et al. Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. Expert Opin Pharmacother. 2016;17:2253–2266.
  • Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012;13:1011–1019.
  • Gobbini E, Chiari R, Pizzutillo P, et al. Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study. Clin Transl Oncol. 2020;22(3):294–301.
  • Camidge DR, Dziadziuszko R, Peters S, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol. 2019;14:1233–1243.
  • Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;S0923-7534(20):39796–9. doi:10.1016/j.annonc.2020.04.478
  • Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19:1654–1667.
  • Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019;30:1121–1126.
  • Facchinetti F, Rossi G, Bria E, et al. Oncogene addiction in non-small cell lung cancer: focus on ROS1 inhibition. Cancer Treat Rev. 2017;55:83–95.
  • Landi L, Chiari R, Tiseo M, et al. Crizotinib in MET -Deregulated or ROS1 -rearranged pretreated non–small cell lung cancer (METROS): a phase II, prospective, multicenter, two-arms trial. Clin Cancer Res. 2019;25:7312–7319.
  • Moro-Sibilot D, Cozic N, Pérol M, et al. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. Ann Oncol. 2019;30:1985–1991.
  • Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial. Lancet Onc. 2019;20:1691–1701.
  • Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trial. Lancet Onc. 2020;21:261–270.
  • Pilotto S, Carbognin L, Karachaliou N, et al. Tracking MET de-addiction in lung cancer: A road towards the oncogenic target. Cancer Treat Rev. 2017;60:1–11.
  • Drilon A, Jeffrey W, Clark JW, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med. 2020;26:47–51.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.